Oncology

Latest News

FDA Approves Breyanzi for Mantle Cell Lymphoma
FDA Approves Breyanzi for Mantle Cell Lymphoma

May 31st 2024

Breyanzi is a CAR T-cell therapy now approved for four subtypes of non-Hodgkin lymphoma.

Science RF-stock.adobe.com
Verastem Begins Submission for Ovarian Cancer Combination

May 24th 2024

appledesign-stock.adobe.com
FDA Approves Bispecific Antibody for Small Cell Lung Cancer

May 17th 2024

FDA Approves Breyanzi for Follicular Lymphoma
FDA Approves Breyanzi for Follicular Lymphoma

May 16th 2024

person holding AML letters wearing purple medical gloves | Image credit: ©Dzmitry  stock.adobe.com
A New Kid on the Block of Therapy for Acute Myeloid Leukemia

May 9th 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Register Now!

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

More News

© 2024 MJH Life Sciences

All rights reserved.